{"id":19606,"date":"2023-04-14T12:22:00","date_gmt":"2023-04-14T04:22:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19606"},"modified":"2024-12-24T12:42:08","modified_gmt":"2024-12-24T04:42:08","slug":"shanghais-pharmalegacy-files-for-ipo-on-star-targets-pre-clinical-rd-expansion","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19606","title":{"rendered":"Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion"},"content":{"rendered":"\n

PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange\u2019s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of pre-clinical research and development (R&D) service facilities, the development of an innovative R&D platform, technical transformation and improvement of the preclinical service industry base, and supplementary working capital.<\/p>\n\n\n\n

Company Background and Services<\/strong>
Founded in 2008, PharmaLegacy specializes in providing top-tier services in pharmacodynamics and pharmacokinetics, non-GLP toxicology, in vitro immunology, and Category III medical device evaluation. The company’s business scope spans a range of therapeutic areas, including immune diseases\/inflammation, tumors, metabolic diseases, bone diseases, eye diseases, and cardiovascular diseases. With a strong track record in pre-clinical research, PharmaLegacy generated RMB 180 million (USD 26.3 million) in revenues and RMB 39.74 million (USD 5.8 million) in net profits during the first three quarters of the previous year.<\/p>\n\n\n\n

Financing and Growth Prospects<\/strong>
In October 2021, PharmaLegacy secured a USD 100 million financing round led by GL Ventures and Sequoia China, demonstrating the market’s confidence in the company’s growth potential. The funds raised will play a crucial role in enhancing PharmaLegacy’s capabilities and expanding its services in the pre-clinical CRO market.<\/p>\n\n\n\n

Conclusion<\/strong>
PharmaLegacy’s IPO filing on the STAR board is a strategic move that aligns with the company’s ambition to strengthen its position in the pre-clinical CRO sector. With the anticipated proceeds, the company is set to invest in infrastructure and innovation, further solidifying its role as a key player in the global pharmaceutical research landscape.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[19,72,2919],"class_list":["post-19606","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-cro-cmo-cdmo","tag-ipo","tag-pharmalegacy-laboratories"],"yoast_head":"\nShanghai's PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange\u2019s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of pre-clinical research and development (R&D) service facilities, the development of an innovative R&D platform, technical transformation and improvement of the preclinical service industry base, and supplementary working capital.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19606\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shanghai's PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19606\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-14T04:22:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-24T04:42:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19606#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19606\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion\",\"datePublished\":\"2023-04-14T04:22:00+00:00\",\"dateModified\":\"2024-12-24T04:42:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19606\"},\"wordCount\":294,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"CRO \\\/ CMO \\\/ CDMO\",\"IPO\",\"PharmaLegacy Laboratories\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19606#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19606\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19606\",\"name\":\"Shanghai's PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-14T04:22:00+00:00\",\"dateModified\":\"2024-12-24T04:42:08+00:00\",\"description\":\"PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange\u2019s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of pre-clinical research and development (R&D) service facilities, the development of an innovative R&D platform, technical transformation and improvement of the preclinical service industry base, and supplementary working capital.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19606#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19606\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19606#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Shanghai's PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion - Insight, China's Pharmaceutical Industry","description":"PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange\u2019s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of pre-clinical research and development (R&D) service facilities, the development of an innovative R&D platform, technical transformation and improvement of the preclinical service industry base, and supplementary working capital.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19606","og_locale":"en_US","og_type":"article","og_title":"Shanghai's PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19606","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-14T04:22:00+00:00","article_modified_time":"2024-12-24T04:42:08+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19606#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19606"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion","datePublished":"2023-04-14T04:22:00+00:00","dateModified":"2024-12-24T04:42:08+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19606"},"wordCount":294,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["CRO \/ CMO \/ CDMO","IPO","PharmaLegacy Laboratories"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19606#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19606","url":"https:\/\/flcube.com\/?p=19606","name":"Shanghai's PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-14T04:22:00+00:00","dateModified":"2024-12-24T04:42:08+00:00","description":"PharmaLegacy Laboratories (Shanghai) Co., Ltd., a Shanghai-based pre-clinical Contract Research Organization (CRO), has reportedly filed for an initial public offering (IPO) with the Shanghai Stock Exchange\u2019s Sci-Tech Innovation Board (STAR). The company anticipates raising RMB 601 million (USD 87.8 million) in proceeds, which will be allocated towards the construction of pre-clinical research and development (R&D) service facilities, the development of an innovative R&D platform, technical transformation and improvement of the preclinical service industry base, and supplementary working capital.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19606#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19606"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19606#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Shanghai’s PharmaLegacy Files for IPO on STAR, Targets Pre-clinical R&D Expansion"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19606"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19606\/revisions"}],"predecessor-version":[{"id":19608,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19606\/revisions\/19608"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}